Statins may reduce prostate cancer risk
Men who have used 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors to reduce their cholesterol levels may be at less risk of developing prostate cancer, according to a case-control study published in the American Journal of Epidemiology.
Men who have used 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors to reduce their cholesterol levels may be at less risk of developing prostate cancer, according to a case-control study published in the American Journal of Epidemiology.
Research was conducted at the Veterans Affairs Medical Center in Portland, Ore, with information about statin use collected from an electronic pharmacy database. One hundred men with prostate cancer and 202 men without the condition were included in the study.
Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio [OR], 0.38; 95% CI, 0.21–0.69).
Studies investigating statin use and incident cancer risk as the primary outcome have been largely observational and have yielded conflicting results. The authors note that their study differed in several ways. The most notable difference was that 36% of the prostate cancer cases and 49% of controls had been prescribed statins at least once for a minimum of 3 months. In most of the other studies, the prevalence of use had varied only 6% to 10%.
Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: A case-control study. Am J Epidemiol. 2005;162:318–325.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
